Lag3 and PD-1 are co-expressed on functionally impaired (“exhausted”) tumor-infiltrating lymphocytes (TILs), thereby contributing to tumor-mediated immune suppression both in preclinical models16,17 and in cancer patients18. Here, PDCD1 is linked to cancer.